NGM Biopharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This NGM Biopharmaceuticals Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
NGM Biopharmaceuticals presents a practical BD-screening case because its returned pipeline contains 18 records and the deal search returned 3 transaction records. The lead returned asset is NGM-120, associated with GFRAL and Cachexia, Colorectal Cancer, Advanced Malignant Solid Neoplasm, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | NGM-120 | NGM Biopharmaceuticals, Inc. | Phase 2 | Pipeline record: GFRAL; Cachexia, Colorectal Cancer, Advanced Malignant Solid Neoplasm. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate | Phase 2 asset with GFRAL exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | NGM-707 | NGM Biopharmaceuticals, Inc. | Phase 2 | Pipeline record: LILRB1 x LILRB2; Bile Duct Neoplasms, Breast Cancer, Colorectal Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics | Phase 2 asset with LILRB1 x LILRB2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | NGM-438 | NGM Biopharmaceuticals, Inc. | Phase 1 | Pipeline record: LAIR1; Uterine Cervix Adenocarcinoma, Bile Duct Neoplasms, Breast Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabetes | Phase 1 asset with LAIR1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | NGM-831 | NGM Biopharmaceuticals, Inc. | Phase 1 | Pipeline record: LILRB4; Bile Duct Neoplasms, Breast Cancer, Colorectal Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate | Phase 1 asset with LILRB4 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | DEL-30 | NGM Biopharmaceuticals, Inc. | Preclinical | Pipeline record: target not returned; Metabolic Dysfunction Associated Steatohepatitis. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics | Preclinical asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2024-12-19 | NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate | Active | total_amount: 608; disclosed: false |
| 2015-02-23 | NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics | Active | upfront_payment: 94; milestone_payment: 390; disclosed: true |
| 2012-03-29 | NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabetes | Active | disclosed: false |
The most relevant returned precedent is: NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate (2024-12-19). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Mirum Pharmaceuticals, Inc. - 2022 Quarterly report: Mirum Pharmaceuticals, Inc. - 2022 Quarterly report Liquidity and Capital Resources Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, selling, general and administrative expenditures, including commercial launch expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Although Livmarli has been approved by the FDA for the treatment of cholestatic pruritus in patients with ALGS one year of age and older, and we expect product revenues to increase as we continue commercial activities, Livmarli may not achieve commercial success. Our principal sources of liquidity are c
- Nemus Bioscience, Inc. - Prospectus(U.S. Stocks): Nemus Bioscience, Inc. - Prospectus(U.S. Stocks) Table of Contents Liquidity and Capital Resources We had cash and cash equivalents of $2,945,312 as of March 31, 2018, as compared to $259,955 as of December 31, 2017. This increase is primarily attributable to the proceeds of $3,250,000 from the Emerald financing along with the $900,000 convertible bridge loan from Emerald as previously discussed. We anticipate that we will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support our corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that we will not have sufficient funds to meet our o
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether NGM Biopharmaceuticals is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
NGM Biopharmaceuticals merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate NGM-120, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
